• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies

tetano

Editor, Senior Moderator
Front Immunol. 2016 Dec 26;7:641. doi: 10.3389/fimmu.2016.00641. eCollection 2016.
[h=1]A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies.[/h] Bernelin-Cottet C[SUP]1[/SUP], Deloizy C[SUP]1[/SUP], Stanek O[SUP]2[/SUP], Barc C[SUP]3[/SUP], Bouguyon E[SUP]1[/SUP], Urien C[SUP]1[/SUP], Boulesteix O[SUP]3[/SUP], Pezant J[SUP]3[/SUP], Richard CA[SUP]1[/SUP], Moudjou M[SUP]1[/SUP], Da Costa B[SUP]1[/SUP], Jouneau L[SUP]1[/SUP], Chevalier C[SUP]1[/SUP], Leclerc C[SUP]4[/SUP], Sebo P[SUP]2[/SUP], Bertho N[SUP]1[/SUP], Schwartz-Cornil I[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The development of influenza A virus (IAV) vaccines, which elicits cross-strain immunity against seasonal and pandemic viruses is a major public health goal. As pigs are susceptible to human, avian, and swine-adapted IAV, they would be key targets of so called universal IAV vaccines, for reducing both the zoonotic risk and the economic burden in the swine industry. They also are relevant preclinical models. However, vaccination with conserved IAV antigens (AGs) in pigs was reported to elicit disease exacerbation. In this study, we assessed whether delivery strategies, i.e., dendritic cell (DC) targeting by the intradermal (ID) or intramuscular (IM) routes, impact on the outcome of the vaccination with three conserved IAV AGs (M2e, NP, and HA2) in pigs. The AGs were addressed to CD11c by non-covalent binding to biotinylated anti-CD11c monoclonal antibody. The CD11c-targeted AGs given by the ID route exacerbated disease. Conversely, CD11c-targeted NP injected by the IM route promoted T cell response compared to non-targeted NP. Furthermore, the conserved IAV AGs injected by the IM route, independently of DC targeting, induced both a reduction of viral shedding and a broader IgG response as compared to the ID route. Our findings highlight in a relevant animal species that the route of vaccine delivery impacts on the protection induced by conserved IAV AGs and on vaccine adverse effects. Finally, our results indicate that HA2 stands as the most promising conserved IAV AG for universal vaccine development.


[h=4]KEYWORDS:[/h] dendritic cells; human; influenza; routes of administration; swine; vaccine

PMID: 28082980 DOI: 10.3389/fimmu.2016.00641
[PubMed - in process]
 
Back
Top Bottom